Results 161 to 170 of about 1,580 (184)
Some of the next articles are maybe not open access.

Mavacamten for Obstructive Hypertrophic Cardiomyopathy in China

JAMA Cardiology, 2023
openaire   +2 more sources

Mavacamten

Reactions Weekly, 2018
openaire   +1 more source

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2020
Pablo García-Pavía   +2 more
exaly  

Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

Annals of Pharmacotherapy, 2023
C Michael White
exaly  

MAVACAMTEN IN HYPERTROPHIC CARDIOMYOPATHY: EFFECTIVE, BUT AFFORDABLE?

Journal of the American College of Cardiology, 2023
Shivani Hanchate   +4 more
openaire   +1 more source

Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model

Journal of Clinical Pharmacology, 2023
Caroline Sychterz   +2 more
exaly  

Reflections on community experience with Mavacamten

Progress in Cardiovascular Diseases
Eiswirth, Clement, Gilliland, Yvonne E.
openaire   +4 more sources

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy

New England Journal of Medicine
Milind Y. Desai   +13 more
openaire   +2 more sources

A Collaborative Approach to Mavacamten Care: A Pharmacist-Nurse Led Mavacamten Monitoring Program

Heart, Lung and Circulation
V. Warner   +11 more
openaire   +1 more source

Impact of the Myosin Modulator Mavacamten on Force Generation and Cross‐Bridge Behavior in a Murine Model of Hypercontractility

Journal of the American Heart Association, 2018
Ranganath Mamidi   +2 more
exaly  
hypertrophic cardiomyopathy
benzylamines
uracil
humans
cardiomyopathy, hypertrophic
echocardiography
3. good health
cardiac myosin inhibitors
cardiac myosin inhibitor
previous   15  16  17  18  19  

Home - About - Disclaimer - Privacy